

Special Issue

Strategies to Increase Vaccination Coverage and Vaccine Confidence 2.0

Message from the Guest Editor

Vaccines are effective and cost-effective preventive interventions against infectious diseases occurring in children and adults. The importance of vaccines is emphasized by economic studies reporting that vaccines for children and adults are associated with low cost-effectiveness ratios and societal savings. Nevertheless, the percentages of vaccination coverage registered in developed and undeveloped countries in the target vaccination populations (children, adults, high-risk individuals, specific population groups) remain below the recommended levels. Vaccine hesitance, defined as a “delay in acceptance or refusal of vaccines despite availability of vaccine services”, is one of the factors explaining suboptimal percentages of vaccination coverage. Vaccine hesitancy depends on the perceived risk of disease, accessibility of vaccines, and vaccine confidence. High confidence in vaccination programs is necessary to achieve high percentages of vaccination coverage. This Special Issue focuses on the strategies and practical solutions to increase the percentages of vaccination coverage by means of increasing vaccine confidence.

Guest Editor

Dr. Pedro Plans-Rubió

1. College of Physicians of Barcelona, 08017 Barcelona, Spain
2. Public Health Agency of Catalonia, Department of Health of Catalonia, 08005 Barcelona, Spain

Deadline for manuscript submissions

closed (30 November 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/85242

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).